AvidinOX + 177Lu-ST2210

AvidinOX + 177Lu-ST2210 is a combination therapeutic approach in which **AvidinOX** (a chemically oxidized form of the glycoprotein avidin, derived from hen eggs) is injected directly into tumor tissue, where it forms stable covalent bonds with tissue proteins, creating an artificial receptor for subsequent targeting. **177Lu-ST2210** is a radiopharmaceutical consisting of 177Lutetium (a beta/gamma-emitting radioisotope), chelated to biotin-DOTA, administered intravenously. Once the AvidinOX is bound to the tumor, the biotinylated radiolabeled compound (177Lu-ST2210) is captured by the tissue-bound AvidinOX, delivering targeted ionizing beta-radiation to the tumor. This approach is designed to allow **localized internal radiotherapy** of inoperable tumors with reduced systemic toxicity, leveraging the selective binding mechanism of AvidinOX and the therapeutic and imaging capabilities of 177Lu. It has been investigated in **phase 1 clinical trials** for **liver metastases from colorectal cancer**, and has been proposed for other solid tumors and lymphoma[3][5][1].

Other names

Oxidised AvidinAvidinOX-Lu-177-DOTA-BiotinAvidinOX-Lu177-DOTA-BiotinAvidinOX-Lu 177-DOTA-Biotin